NutraLife BioSciences (NLBS) 10-K 19 Mar 21 2019 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2019	Mar. 19, 2021	Jun. 30, 2020
Cover [Abstract]
Entity Registrant Name	NUTRALIFE BIOSCIENCES, INC
Entity Central Index Key	0001563463
Document Type	10-K
Document Period End Date	Dec. 31, 2019
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 3,459,905
Entity Common Stock, Shares Outstanding		160,740,190
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2019

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Current Assets:
Cash	$ 14,828	$ 419,975
Accounts receivable, net of allowance for doubtful accounts in the amount of $1,500 and $31,000	11,799	43,503
Inventories	490,173	291,040
Prepaid and other current assets	87,627	115,003
Total current assets	604,427	869,521
Property and equipment, net	2,376,647	925,808
Operating lease right-of-use assets	794,531
Intangible asset	655,086
Other assets	35,000	35,000
Total Assets	4,465,691	1,830,329
Current Liabilities:
Accounts payable	172,987	243,502
Accrued expenses	413,194	468,838
Customer deposits	9,350	84,686
Liability for stock to be issued	265,500
Current portion of finance leases	20,000	3,836
Current portion of operating lease liability	141,674
Convertible notes, related parties, net of unamortized discount of $290,961 and $280,400	1,164,039	199,600
Total current liabilities	2,186,744	1,000,462
Liabilities:
Operating lease liability, net of current portion	653,057
Finance leases, net of current portion	36,773	14,614
Total liabilities	2,876,574	1,015,076
Stockholders' Equity
Preferred stock; $0.001 par value, 10,000 shares authorized: 1,000 shares Series A issued and outstanding	1	1
Common stock; $0.0001 par value, 499,990,000 authorized shares; 140,976,183 and 97,315,941 shares issued and outstanding	14,092	9,732
Additional paid-in-capital	40,415,885	35,638,978
Accumulated deficit	(38,840,861)	(34,833,458)
Total stockholders' equity	1,589,117	815,254
Total Liabilities and Stockholders' Equity	$ 4,465,691	$ 1,830,329

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Allowance for doubtful accounts	$ 1,500	$ 31,000
Unamortized discount	$ 290,961	$ 280,400
Preferred stock, shares par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000	10,000
Common stock, shares par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	499,990,000	499,990,000
Common stock, shares issued	140,976,183	97,315,941
Common stock, shares outstanding	140,976,183	97,315,941
Series A Preferred Stock [Member]
Preferred stock, shares authorized	1,000
Preferred stock, shares issued	1,000	1,000
Preferred stock, shares outstanding	1,000	1,000

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Statement [Abstract]
Sales	$ 2,133,624	$ 3,711,327
Cost of Sales	1,535,490	2,211,039
Gross Profit	598,134	1,500,288
OPERATING EXPENSES
Advertising and promotion	272,634	265,568
Stock-based compensation	610,987	1,070,050
General and administrative	3,109,887	2,070,714
Total operating expenses	3,993,508	3,406,332
LOSS FROM OPERATIONS	(3,395,374)	(1,906,044)
OTHER INCOME (EXPENSE)
Other income (expense)	58,020	(16,739)
Loss on stock settlement of accounts payable		(18,004)
Finance costs-related parties	(662,124)	(130,763)
Interest expense	(7,925)	(2,987)
Total other income (expense)	(612,029)	(168,493)
Loss before income taxes	(4,007,403)	(2,074,537)
Income tax expense
NET LOSS	$ (4,007,403)	$ (2,074,537)
Net loss per weighted average common share - basic and diluted	$ (0.04)	$ (0.02)
Number of weighted average common shares outstanding - basic and diluted	113,275,262	87,323,469

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2017	$ 1	$ 8,144	$ 33,411,300	$ (32,758,921)	$ 660,524
Balance, shares at Dec. 31, 2017	1,000	81,448,561
Shares issued for cash		$ 703	617,629		618,332
Shares issued for cash, shares		7,024,704
Shares issued to settle accounts payable		$ 17	49,477		49,494
Shares issued to settle accounts payable, shares		169,159
Shares issued for services		$ 498	1,069,552		1,070,050
Shares issued for services, shares		4,976,849
Shares issued for equipment		$ 170	105,059		105,229
Shares issued for equipment, shares		1,696,668
Shares issued in connection with convertible debt		$ 200	190,276		190,476
Shares issued in connection with convertible debt, shares		2,000,000
Warrants issued in connection with convertible debt			176,798		176,798
Beneficial conversion feature			18,888		18,888
Net loss				(2,074,537)	(2,074,537)
Balance at Dec. 31, 2018	$ 1	$ 9,732	35,638,979	(34,833,458)	815,254
Balance, shares at Dec. 31, 2018	1,000	97,315,941
Shares issued for cash		$ 3,617	2,778,042		2,781,659
Shares issued for cash, shares		36,172,710
Shares issued to settle accounts payable		$ 93	93,307		93,400
Shares issued to settle accounts payable, shares		934,000
Shares issued for services		$ 319	610,668		610,987
Shares issued for services, shares		3,190,432
Shares issued in connection with convertible debt		$ 151	220,229		220,380
Shares issued in connection with convertible debt, shares		1,563,100
Warrants issued in connection with convertible debt			247,800		247,800
Beneficial conversion feature			127,900		127,900
Shares issued in connection with the purchase of intangible assets		$ 180	318,960		319,140
Shares issued in connection with the purchase of intangible assets, shares		1,800,000
Debt converted to equity			380,000		380,000
Net loss				(4,007,403)	(4,007,403)
Balance at Dec. 31, 2019	$ 1	$ 14,092	$ 40,415,885	$ (38,840,861)	$ 1,589,117
Balance, shares at Dec. 31, 2019	1,000	140,976,183

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
OPERATING ACTIVITIES:
Net loss	$ (4,007,403)	$ (2,074,537)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock based compensation	610,987	1,070,050
Depreciation	64,849	66,033
Amortization of debt discount	585,519	105,763
Amortization of right of use asset	106,056
Amortization of intangible asset	59,554
Bad debts (recoveries)	(29,500)	84,183
Loss on the settlement of accounts payable		18,004
Changes in operating assets and liabilities:
Decrease (increase) in accounts receivable	61,205	(127,686)
Increase in inventory	(199,133)	(128,846)
Decrease in prepaid expenses	27,376	217,457
Increase in accounts payable	22,885	187,487
(Decrease) increase in accrued expenses	(55,644)	262,733
(Decrease) increase in customer deposits	(75,336)	84,686
Decrease in operating lease liabilities	(105,856)
Net Cash Used in Operating Activities	(2,934,441)	(234,673)
INVESTING ACTIVITIES:
Security deposits		(35,000)
Acquisition of intellectual property	(130,000)
Purchases of property and equipment	(1,464,494)	(581,632)
Net Cash Used in Investing Activities	(1,594,494)	(616,632)
FINANCING ACTIVITIES:
Common shares issued for cash	2,781,659	618,332
Payments on finance leases	(12,871)
Proceeds from convertible debt	1,455,000
Cash proceeds from debt issuance		480,000
Repayment of debt - related party	(100,000)
Net Cash Provided by Financing Activities	4,123,788	1,098,332
Net increase (decrease) in cash	(405,147)	247,027
CASH, beginning of year	419,975	172,948
CASH, end of year	14,828	419,975
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash paid for interest	3,376	2,987
Non-Cash Investing and Financing Activities:
Acquisition of equipment under finance leases	51,194	19,179
Shares issued for the issuance of debt		190,476
Warrants issued for the issuance of debt	247,800	176,798
Beneficial conversion feature	127,900
Shares issued to acquire fixed assets		105,229
Shares issued to settle accounts payable	93,400	49,494
Shares issued and issuable for the acquisition of intellectual property	584,640
Debt converted to equity	380,000
Shares issued in connection with convertible debt	220,380
Right of use asset additions under ASC 842	885,194
Operating lease liabilities under ASC 842	$ 900,587

Nature of Operations

Nature of Operations	12 Months Ended
	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations	NOTE 1 - NATURE OF OPERATIONS NutraLife BioSciences, Inc. F/K/A NutraFuels, Inc. (We, or the Company) is the producer and distributor of nutritional supplements that uses micro molecular formulae and a utilization of an oral spray to provide faster and more efficient absorption. Our products are sold to private label distributors who sell the products we manufacture under their own brand name as well as under our own brand names. In February of 2019, NutraFuels, Inc. approved an amendment to its Articles of Incorporation to change its name to Nutralife Biosciences, Inc. The name change was made effective on March 6, 2019.

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	NOTE 2 - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES a) Basis of Presentation The accompanying financial statements have been prepared in accordance with Generally Accepted Accounting Principles (“GAAP”) in the United States of America (“U.S.”) as promulgated by the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) and with the rules and regulations of the U.S Securities and Exchange Commission (“SEC”). b) Reclassifications Reclassifications occurred to certain prior year amounts in order to conform to the current year presentation. The reclassifications have no effect on the reported net loss. c) Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Precision Analytic Testing, LLC, NutraDerma Technologies, Inc., PhytoChem Technologies, Inc. and TransDermalRX, Inc. We operate as one reportable segment. All material intercompany transactions and balances have been eliminated in consolidation. d) Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. e) Inventories Inventories are stated at the lower of cost or net realizable value utilizing the weighted average method of valuation and consist of raw materials and finished goods. As of December 31, inventory consists of the following: 2019 2018 Raw Materials $ 206,238 $ 219,638 Finished Goods 283,935 71,402 $ 490,173 $ 291,040 f) Allowance for Doubtful Accounts We establish the existence of bad debts through a review of several factors including historical collection experience, current aging status of the customer accounts, and financial condition of our customers. The allowance for doubtful accounts is $1,500 and $31,000 as of December 31, 2019 and 2018, respectively. The activity for the allowance for doubtful accounts for the years ended December 31, 2019 and 2018 is as follows: Balance at Beginning of Year Charged to expense Deductions from Reserve Balance at End of Year Year ended December 31, 2019 $ 31,000 - 29,500 $ 1,500 Year ended December 31, 2018 $ - 31,000 - $ 31,000 g) Property and Equipment All property and equipment are recorded at cost and depreciated over their estimated useful lives, generally three, seven and twelve years, using the straight-line method. Leasehold improvements are depreciated over the shorter of their estimated useful lives, which is generally three years, or the related lease term. Upon sale or retirement, the cost and related accumulated depreciation are eliminated from their respective accounts, and the resulting gain or loss is included in the results of operations. Repairs and maintenance charges, which do not increase the useful lives of the assets, are charged to operations as incurred. h) Revenue Recognition The Company adopted ASU 2014-09, “Revenue from Contracts with Customers” (Topic 606) and other associated standards on January 1, 2018, using the modified retrospective method, which did not have a material impact on the timing and amount of product revenues. The new revenue recognition standard prescribes a five-step model that focuses on transfer of control and entitlement to payment when determining the amount of revenue to be recognized. Under the new guidance, an entity is required to perform the following five steps: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation. The Company generates revenues from the sale of products. The product is invoiced, and the revenue is recognized upon shipment or once transfer of risk has passed to the customer, which is the point at which the Company has satisfied its performance obligation. Payments received in advance from customers are recorded as customer deposits until earned, at which time revenue is recognized. We recognize certain revenues under bill and hold arrangements with two customers when the Company has fulfilled all of its performance obligations, the units are segregated for the specific customer only, and the goods are ready for physical transfer to the customer in accordance with their defined contract delivery schedule. For any requested bill and hold arrangement, we make an evaluation as to whether the bill and hold arrangement qualifies for revenue recognition. The customer must initiate the request for the bill and hold arrangement. The customer must make a fixed commitment to purchase the items. The risk of ownership is passed to the customer, and payment terms are not modified. The Company’s revenues accounted for under ASC 606 do not require significant estimates or judgments based on the nature of the Company’s revenue. The Company’s contracts do not include multiple performance obligations or variable consideration. All of the Company’s sales resulted from contracts with customers for the years ended December 31, 2019 and 2018. i) Shipping and Handling Costs Shipping and handling costs are expensed as incurred and included in cost of sales. Billings for shipping and handling are reflected within sales in the accompanying consolidated statements of operations. j) Income Taxes The Company follows the provisions of ASC 740-10, Accounting for Uncertain Income Tax Positions. When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of ASC 740-10, the benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above should be reflected as a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination. The tax years 2017-2019 for the Company remain open for IRS audit. The Company has received no notice of audit or any notifications from the IRS for any of the open tax years. k) Net Loss Per Share Basic loss per share excludes dilution and is computed by dividing the loss attributable to stockholders by the weighted-average number of shares outstanding for the period. Diluted loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that shared in the earnings of the Company. Diluted loss per share is computed by dividing the loss available to stockholders by the weighted average number of shares outstanding for the year and dilutive potential shares outstanding unless consideration of such dilutive potential shares would result in anti-dilution. For the years ended December 31, 2019 and 2018, respectively, the following warrants and convertible notes were excluded from the computation of net loss per share: 2019 2018 Warrants 21,819,858 18,210,402 Convertible Notes payable and accrued interest 3,900,727 1,325,000 25,720,585 19,535,402 l) Financial Instruments and Fair Value Measurements The carrying value of the Company’s current consolidated financial instruments, which include cash, accounts receivable, accounts payable and accrued liabilities approximate their fair values because of the short-term maturities of these instruments. The carrying value of the Company’s indebtedness approximates their fair values because of the short-term maturities and rates of interest of these instruments. m) Impairment of Long-Lived Assets A long-lived asset is tested for impairment whenever events or changes in circumstances indicate that its carrying value amount may not be recoverable. An impairment loss is recognized when the carrying amount of the asset exceeds the sum of the undiscounted cash flows resulting from its use and eventual disposition. The impairment loss is measured as the amount by which the carrying amount of the long-lived assets exceeds its fair value. There were no impairments recognized during the years ended December 31, 2019 and 2018. n) Advertising Advertising costs are charged to operations as incurred and are included in operating expenses. The Advertising expenses are approximately $272,600 and $265,500 for the years ended December 31, 2019 and 2018, respectively. o) Intangible Asset Intangible asset represents the value assigned to intellectual property and is amortized based on the economic benefit expected to be realized. p) Leases On January 1, 2019, the Company adopted FASB ASU 2016-02, Leases (ASC 842) and other associated standards, which defines a lease as any contract that conveys the right to use a specific asset for a period of time in exchange for consideration. ASC 842 requires the recognition of the right-of-use assets and related operating and finance lease liabilities on the balance sheet and the disclosure of key information about certain leasing arrangements. As permitted by ASC 842, the Company elected the adoption date of January 1, 2019, which is the initial date of application. As a result, the consolidated balance sheet prior to January 1, 2019 was not restated, continues to be reported under ASC Topic 840, Leases, or ASC 840, which did not require the recognition of operating lease liabilities on the balance sheet, and is not comparative. Under ASC 842, all leases are required to be recorded on the balance sheet and are classified as either operating leases or finance leases (formerly called capital leases). The lease classification affects the expense recognition in the income statement. Operating lease charges are recorded entirely in operating expenses. Finance lease charges are split, where amortization of the right-of-use asset is recorded in operating expenses and an implied interest component is recorded in interest expense. The expense recognition for operating leases and finance leases under ASC 842 is substantially consistent with ASC 840. As a result, there is no significant difference in the Company’s results of operations presented in the consolidated statement of operations for each period presented. Leases are classified as a finance lease if any of the following criteria are met: 1. The lease transfers ownership of the underlying asset to the lessee by the end of the lease term. 2. The lease grants the lessee an option to purchase the underlying asset that the lessee is reasonably certain to exercise. 3. The lease term is for the major part of the remaining economic life of the underlying asset. 4. The present value of the sum of lease payments and any residual value guaranteed by the lessee equals or exceeds substantially all of the fair value of the underlying asset. 5. The underlying asset is of such a specialized nature that it is expected to have no alternative use to the lessor at the end of the lease term. For any leases that do not meet the criteria identified above for finance leases, the Company treats such leases as operating leases. As of December 31, 2019, the Company has two finance leases and three operating leases. Under the new guidance, both finance and operating leases are reflected on the balance sheet as lease or “right-of -use” assets and lease liabilities. There are some exceptions, which the Company has elected in its accounting policies. For leases with terms of twelve months or less, or below the Company’s general capitalization policy threshold, the Company elects an accounting policy to not recognize lease assets and lease liabilities for all asset classes. The Company recognizes lease expense for such leases generally on a straight-line basis over the lease term. The Company determines if a contract is a lease at the inception of the arrangement. The Company reviews all options to extend, terminate, or purchase its right-of-use assets at the inception of the lease and accounts for these options when they are reasonably certain to be exercised. Certain leases contain non-lease components, such as common area maintenance, which are generally accounted for separately. In general, the Company will assess if non-lease components are fixed and determinable, or variable, when determining if the component should be included in the lease liability. For purposes of calculating the present value of the lease obligations, the Company utilizes the implicit interest rate within the lease agreement when known and/or determinable, and otherwise utilizes its incremental borrowing rate at the time of the lease agreement. The related right-of-use asset is initially measured at cost, which primarily comprises of the initial amount of the lease liability. Lease expense for operating leases consists of the lease payments plus any initial direct costs and is recognized on a straight-line basis over the lease term. Included in lease expense are any variable lease payments incurred in the period that were not included in the initial lease liability. Lease expense for finance leases consists of the amortization of the right-of-use asset on a straight-line basis over the lease term and interest expense determined on an amortized cost basis. The lease payments are allocated between a reduction of the lease liability and interest expense. As permitted under ASU 2018-11, the Company elected the modified retrospective approach to adopt the new lease standard. Under this approach, the Company initially applied the new leases standard at the adoption date of January 1, 2019 and would have recognized a cumulative-effect adjustment, if appropriate, to the opening balance of retained earnings in the period of adoption. No cumulative-effect adjustment was recognized. The Company’s reporting for the comparative periods prior to 2019 in the financial statements will be presented in accordance with the existing U.S. GAAP in effect for 2018 and earlier (ASC Topic 840, Leases The impact of the adoption of ASC 842 on the balance sheet as of December 31, 2018 was: As Reported December 31, 2018 Adoption of ASC 842 Increase (Decrease) Balance, January 1, 2019 Operating Lease Right-of-Use-Asset $ - $ 781,030 $ 781,030 Total Assets $ 1,830,329 $ 781,030 $ 2,611,359 Operating Lease Liabilities-Current Portion $ - $ 88,121 $ 88,121 Total Current Liabilities $ 1,000,461 $ 88,121 $ 1,088,582 Operating Lease Liabilities-Net of Current Portion $ - $ 707,524 $ 707,524 Deferred Rent $ 14,614 $ (14,614 ) $ - Total Liabilities $ 1,015,075 $ 781,030 $ 1,796,105 Total Liabilities and Stockholders’ Equity $ 1,830,329 $ 781,030 $ 2,611,359 q) Recent Accounting Pronouncements In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15th, 2020, with early adoption permitted. The Company is currently evaluating the impact of this standard on its consolidated financial statements and related disclosures. In August 2020, the FASB issued ASU 2020-06, “Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity,” which simplifies and clarifies certain calculation and presentation matters related to convertible and equity and debt instruments. Specifically, ASU-2020-06 removes requirements to separately account for conversion features as a derivative under ASC Topic 815 and removing the requirement to account for beneficial conversion features on such instruments. Accounting Standards Update 2020-06 also provides clearer guidance surrounding disclosure of such instruments and provides specific guidance for how such instruments are to be incorporated in the calculation of Diluted EPS. The guidance under ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. The Company will adopt this standard using a modified retrospective approach effective January 1, 2021. The Company is currently evaluation the effects of adoption on its consolidated financial statements. Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying consolidated financial statements.

Liquidity and Going Concern Con

Liquidity and Going Concern Considerations	12 Months Ended
	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Liquidity and Going Concern Considerations	NOTE 3 - LIQUIDITY AND GOING CONCERN CONSIDERATIONS Our financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. We sustained a net loss of approximately $4.0 and $2.1 million for the years ended December 31, 2019 and 2018, respectively, and have an accumulated deficit of approximately $38.8 million at December 31, 2019. These conditions raise substantial doubt about our ability to continue as a going concern. In December 2019, a novel strain of coronavirus was reported to have surfaced in China. The spread of this virus caused various business disruptions including temporary closures to the Company’s offices and facilities. While these disruptions are currently expected to be temporary, there is considerable uncertainty around the duration. Therefore, the Company expects this matter to negatively impact its operating results. The related financial impact and duration cannot be reasonably estimated at this time. The Company is currently in the process of raising capital to complete and finalize the build-out of its facility in Deerfield Beach for the purpose of consolidating its operations. The structure of the capital raise is currently in development. The Company is continuing its path to profitability through increased business development, marketing and sales of the Company’s multiple lines of topical, ingestible and skincare health and wellness products. The Company is also focused on completing an efficacy clinical study on its patented mosquito bug patch with plans upon a successful conclusion to launch globally in the very near future, adding to the Company’s suite of wellness products. The independent auditors’ reports on our financial statements for the years ended December 31, 2019 and 2018 contain explanatory paragraphs expressing substantial doubt as to our ability to continue as a going concern. Failure to successfully continue to grow operational revenues could harm our profitability and adversely affect our financial condition and results of operations. We face all of the risks inherent in a new business, including the need for significant additional capital, management’s potential underestimation of initial and ongoing costs, and potential delays and other problems in connection with establishing sales channels. We are continuing our plan to further grow and expand operations and seek sources of capital to pay our contractual obligations as they come due. Management believes that its current operating strategy will provide the opportunity for us to continue as a going concern as long as we are able to obtain additional financing; however, there is no assurance this will occur. The accompanying consolidated financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern.

Property and Equipment, Net

Property and Equipment, Net	12 Months Ended
	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	NOTE 4 – PROPERTY AND EQUIPMENT, NET A summary of property and equipment at December 31, is as follows: 2019 2018 Furniture and equipment $ 1,959,694 $ 910,224 Leasehold improvements 840,728 374,934 Property and equipment, at cost 2,800,422 1,285,158 Less: accumulated depreciation (423,775 ) (359,350 ) $ 2,376,647 $ 925,808 Depreciation expense for the years ended December 31, 2019 and 2018 totaled $64,849 and $66,033 respectively.

Intangible Asset

Intangible Asset	12 Months Ended
	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Asset	NOTE 5 – INTANGIBLE ASSET In February 2019, the Company acquired certain intellectual property consisting of patent rights. The aggregate purchase price paid in connection with the patent purchase was $714,640, consisting of $130,000 cash, and 3,300,000 shares of the Company’s common stock valued at $0.177 per share or an aggregate of $584,640. Of the 3,300,000 shares, 1,800,000 shares were provided at closing and 1,500,000 were to be provided one year thereafter. These shares have not been issued and the Company is in negotiations with the seller to extend the issuance of the shares. The acquired patent is amortized over its remaining estimated useful life of approximately 11 years. Amortization for the year ended December 31, 2019 totaled approximately $59,000. The estimated annual amortization expense for the next five years and thereafter is as follows: 2020 $ 65,000 2021 65,000 2022 65,000 2023 65,000 2024 65,000 Thereafter 330,086 $ 655,086

Accrued Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2019
Payables and Accruals [Abstract]
Accrued Expenses	NOTE 6 – ACCRUED EXPENSES A summary of accrued expenses at December 31, is as follows: Name 2019 2018 Officer – Bonus $ 300,000 $ 200,000 Deferred rent - 15,393 Interest payable 42,059 - Miscellaneous Accrual 9,561 24,771 Royalty Fees - 85,000 Other current liabilities 61,574 - Accrued rent - 143,674 $ 413,194 $ 468,838

Notes Payable

Notes Payable	12 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
Notes Payable	NOTE 7 – NOTES PAYABLE In the fourth quarter of 2019, the Company received proceeds aggregating $455,000 in connection with multiple short-term convertible promissory notes that were amended to be due in November and December of 2020. The notes bear interest at 10% - 12% for the term of the note. Each noteholder has the right to convert all the outstanding principal and accrued unpaid interest to the Company’s common stock at a price ranging from $.085 to $0.10 per share. Additionally, an aggregate of 3,222,800 warrants were issued to the noteholders. 722,800 of these warrants are exercisable at $0.30 per share and expire one year from the date of each respective note and may be extended for an additional year if the underlying stock price at the time of expiration is at or below the exercise price of $0.10 per share. 2,500,000 of these warrants are exercisable at $0.10 per share. These warrants have expired, however, are expected to be extended an additional year. These notes are currently in default. Additionally, 418,800 shares were issued to certain note holders as additional consideration. The common stock and warrants issued to the noteholders are treated as debt discounts. The gross proceeds of the notes were allocated to debt, warrants and common shares issued on a relative fair value basis. The notes also included a beneficial conversion feature (BCF). The debt discounts associated with the warrants, BCF and common stock issuances are amortized through the earlier of the conversion of the notes into common stock, or the maturity date of the notes, on a straight-line basis which approximates the effective interest method due to the short-term nature of the notes. Amortization of the debt discount is reported as finance costs – related parties in the Statement of Operations. Three of the convertible notes issued in 2019 included issuances of common shares to the investors as inducements for the loans. The Company allocated $106,280 of the gross proceeds to the stock issuances, on a relative fair value basis, which has been recorded as a debt discount. Total amortization associated with the stock issuances related debt discount was $72,166 for the year ended December 31, 2019. The Company allocated $247,800 of the gross proceeds to the warrants, on a relative fair value basis. In addition, because the effective conversion prices of the 2019 notes were less than the fair value of the underlying common stock on the issuance date, the Company allocated $127,900, the intrinsic value of that beneficial conversion feature, to additional paid-in capital. Total amortization associated with the warrants debt discount was $97,785 for the year ended December 31, 2019. Total amortization associated with the beneficial conversion feature debt discount was $134,054 for the year ended December, 31, 2019. The warrants’ relative fair value was calculated using the Black-Scholes Merton valuation model with the following inputs: an expected and contractual life of twelve months, an assumed volatility of 154.8%, zero dividend rate, and a risk free rate of 2.50%. The 2019 warrants are classified in equity as additional paid-in capital. In October 2018, we entered into two short term 10% notes for $75,000 cash, which included the issuance of 2,000,000 warrants to purchase common stock. These notes were repaid in January 2019. In November 2018 we entered into a short term 10% promissory note for $25,000 due in December of 2018. The note provided for a stock grant of 50,000 shares which were not issued and was convertible at $.20 per share. The note was amended in March 2019 and was paid with accrued interest. The amendment also provided for a stock grant totaling 100,000 shares which were issued in March 2019.

Convertible Notes Payable to Sh

Convertible Notes Payable to Shareholder	12 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
Convertible Notes Payable to Shareholder	NOTE 8 - CONVERTIBLE NOTES PAYABLE TO SHAREHOLDER In March 2019, the Company received proceeds of $200,000 from a shareholder, pursuant to a short-term promissory note payable, bearing interest at an annual rate of 3%, due April 20, 2019. On April 1, 2019, the note and accrued interest were satisfied by converting to 2,352,941 shares common stock at $0.085 per share. In June 2019, the Company entered into an Investment Agreement that included a secured convertible 5.75% promissory note payable for $1,000,000 with a shareholder. The note is subject to a security agreement whereby the first four Ennea Processors the Company has committed to commercialize and monetize will be secured as collateral for the note as well as current and future assets of the Company and its subsidiaries. The payment terms of the note are interest only payments from July 7, 2019 through December 7, 2019 and commencing January 7, 2020, the Company was to make equal monthly installment payments that include principal and interest through the Maturity Date of December 7, 2020. Included in the Investment Agreement is a royalty agreement whereby the investor received 500,000 shares of the Company’s common stock and will be entitled to a royalty of 8.5% from the revenue generated from the “collateral processors” while the principal is outstanding and 5% thereafter on the first two collateral processors for a period of 10 years. These 500,000 shares of common stock were valued at $95,500 using the trading price on the date of the agreement and was treated as a debt discount, amortized over the term of the note on a straight-line basis. Amortization associated with this debt discount was $31,836 for the year ended December 31, 2019. In addition to the collateral, the note is secured by a Pledge Agreement from a related-party that included a mortgage lien on certain real property as additional collateral. As compensation for providing the additional collateral, the pledgor received 500,000 shares of the Company’s common stock. Pursuant to the agreement, the Company will also make monthly payments equal to the interest paid on the note commencing on December 5, 2019, and 8.5% of the revenue generated from the collateral processors while the principal is outstanding and 5% thereafter on the first two machines commercialized or monetized by the company. Collateral processors are not yet in service. Therefore, revenue generated from them and the related royalties due cannot be estimated at this time and will be expensed as incurred in the future. The 500,000 shares of common stock issued as compensation for providing additional collateral were also valued at $95,000 using the trading price on the date of the agreement and was treated as a prepaid expense, amortized over the term of the note on a straight-line basis. Amortization associated with this consideration was $31,836 for the year ended December 31, 2019, and is included in stock based compensation of the Statement of Operations. The Company is currently in default of its note, however, the parties to this agreement are in negotiation to reach settlement terms.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2019
Equity [Abstract]
Stockholders' Equity	NOTE 9 - STOCKHOLDERS’ EQUITY Series A Preferred Stock The Company has 10,000 shares of Preferred Stock authorized. 1,000 shares has been designated as Series A Preferred Stock and is not entitled to dividends or liquidation preferences. Each share has voting rights equal to 500,000 shares of the Company’s common stock. In 2012, Edgar Ward was granted 1,000 shares of Series A voting stock for $1,000. Series B Preferred Stock On September 30, 2020, we designated one hundred and ten (110) shares of the preferred stock of the Company, par value $0.0001 as Series B Convertible Preferred Stock (the “Series B Preferred Stock”). The shares of Series B Preferred Stock are convertible at a rate of 1 share of Series B Preferred Stock to 149,567 shares of common stock, par value $0.0001 per share of the Company (the “Common Stock”). Holders of Series B Preferred Stock of the Company may convert their shares of Series B Preferred Stock into Common Stock at any time following January 1, 2021 (the “Permitted Conversion Date”). The Series B Preferred Stock is subject to an ownership limitation, pursuant to which no holder of Series B Preferred Stock will be entitled to convert such investor’s shares of Series B Preferred Stock into shares of Common Stock if such conversion would result in ownership of more than 4.99% of the outstanding shares of Common Stock of the Company. Each share of Series B Preferred Stock will vote together with the holders of the Common Stock on any matter submitted to the shareholders of the Company. Each share of Series B Preferred Stock shall be entitled to a number of votes equal to the number of shares of Common Stock into which the Series B Preferred Stock may convert at the time such vote is made. The Series B Preferred Stock will participate in any dividends, distributions or payments to the holders of the Common Stock on an as-converted basis. The Series B Preferred Stock does not have any liquidation preference over the holders of Common Stock of the Company. Once issued, certain shares of the Series B Preferred Stock are redeemable at the election of the Company at any time prior to the Permitted Conversion Date pursuant to a separate written agreement between the holders of the Series B Preferred Stock and the Company. Settlement Agreement In March 2019, the Company reached an agreement with its third-party lender in connection with their $2,000,000 2018 “Investment Agreement” whereby the Company received only two payments from this lender aggregating $380,000 during 2018. The lender was in default of this agreement and thereby settled by agreeing to fund an additional $1,000,000 for 13,764,705 restricted shares of common stock, a warrant to purchase an additional 10 million common shares at price of $0.20 per share or an aggregate of $2 million under the terms set forth in the agreement, expiring on March 4, 2022, and an option to purchase an additional 7,647,058 common shares at the purchase price of $0.085 per share or an aggregate of $650,000 at any time prior to April 8, 2019. This option was never exercised and therefore expired. In connection with this agreement, the $380,000 previously funded was reclassified to additional paid-in capital. Other The Company issued 934,000 shares to settle accounts payable aggregating $93,400 during 2019. The Company issued an aggregate of 3,190,432 shares for services aggregating $610,987 during 2019. During 2019, the Company has recorded an aggregate of $375,700 to Additional Paid-in Capital resulting from Beneficial Conversion features and warrants issued in connection with convertible debt. The Company issued an aggregate of 4,976,849 shares for services aggregating $1,070,050 during 2018. In February 2018, the Company issued 169,159 shares of common stock valued at $49,494 to settle accounts payable of $31,490. The Company recorded a loss on settlement of $18,004 in connection with this settlement. In February 2018, the Company issued 2,000,000 shares of common stock valued at $569,200 for the acquisition of production equipment. The holder returned the 2,000,000 shares to the Company for cancellation on November 1, 2018 pursuant to a settlement agreement dated September 7, 2018. In December 2018 the Company issued 1,696,968 shares of common stock valued at $105,229 in exchange for production equipment from an unrelated third party. Subsequent issuances In 2020, the Company issued an aggregate of 1,932,076 shares of common stock for $0.065 per share for cash. During 2020, the Company issued 3,150,000 shares of common stock in connection with convertible notes payable. In November 2020, the Company issued 12,500,000 shares of common stock in exchange for 250 shares of Series X Convertible Preferred Stock of Lord Global Corporation in connection with a Stock Purchase Agreement. During 2020, we designated 110 shares of the preferred stock of the Company, par value $0.0001, as Series B Convertible Preferred Stock, and issued 20 shares.

Leases

Leases	12 Months Ended
	Dec. 31, 2019
Leases [Abstract]
Leases	NOTE 10 – LEASES In conjunction with the new guidance for leases, as defined by the FASB with ASU 2016-02, Leases The Company leases its office and warehouse facilities located in Coconut Creek, Florida under a non-cancelable operating lease agreement that expires in February 2022. In June 2017, the Company entered into a lease for an additional facility located in Deerfield Beach, Florida under a non-cancelable operating lease. The term of the lease is for 86 months beginning on January 1, 2018 and calls for yearly 3% increases to base rent, with monthly payments that commenced in March 2018. In July and September of 2019, the Company’s wholly owned subsidiary, Phytochem, entered into two separate lease agreements for office and warehouse space located in Onalaska, Wisconsin, that commenced on August 1 and October 1, respectively. Each lease is for six-month terms with four (4) renewal options to extend for six additional months. The Company expects to occupy these facilities for the full term of these leases totaling 30 months and the leases call for annual 3% increases to base rent. In addition to rent, the Company pays certain insurance, maintenance, and other costs related to the rented spaces. In the December 31, 2019 consolidated balance sheet, the Company has recorded an aggregate right-of-use asset of approximately $795,000 and a lease liability of $795,000, of which $141,674 is reported as a current liability. The weighted average remaining lease term is 54 months and the weighted average discount rate used in 10%. The following table presents a reconciliation of the undiscounted future minimum lease payments remaining under the operating leases reported as operating lease liability on the consolidated balance sheet as of December 31, 2019: Undiscounted future minimum lease payments: 2020 $ 215,000 2021 221,000 2022 182,000 2023 184,000 2024 190,000 Thereafter 16,000 Total undiscounted future minimum lease payments 1,008,000 Less: amount representing imputed interest (213,000 ) Operating lease liability $ 795,000 Lease expense for the operating leases was approximately $297,000 and $256,000 for the years ended December 31, 2019 and 2018, respectively. Finance Leases: The Company has acquired certain equipment under agreements that are classified as finance leases. The cost of the equipment under finance leases is included in the balance sheet as property and equipment. The finance lease equipment was approximately $110,372 and $19,179 as of December 31, 2019 and 2018, respectively and is not yet in service, accordingly there has been no depreciation expense on this equipment. Minimum lease payments required by these finance leases are as follows: Undiscounted future minimum lease payments: 2020 $ 24,000 2021 24,000 2022 17,000 2023 2,100 Total undiscounted future minimum lease payments 67,100 Less: amount representing interest (10,300 ) Less: current portion (20,000 ) Present value of minimum lease payments, net of current portion $ 36,800

Equity Warrants

Equity Warrants	12 Months Ended
	Dec. 31, 2019
Warrants and Rights Note Disclosure [Abstract]
Equity Warrants	NOTE 11 – EQUITY WARRANTS At December 31, our warrants outstanding are as follows: By Exercise Price: 2019 2018 Warrants - $0.10 2,500,000 - Warrants - $0.20 13,302,941 2,950,000 Warrants - $0.30 722,800 - Warrants - $0.35 5,294,117 7,144,117 Warrants - $0.50 - 7,877,000 Warrants - $0.75 - 114,286 Warrants - $1.00 - 124,999 Total outstanding 21,819,858 18,210,402 Warrants Balance, January 1, 2018 16,431,285 Warrants Issued 8,244,117 Warrants Exercised - Warrants Expired (6,465,000 ) Balance, December 31, 2018 18,210,402 Warrants Issued 13,575,741 Warrants Exercised - Warrants Expired (9,966,285 ) Balance, December 31, 2019 21,819,858

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 12 - INCOME TAXES We recognize deferred tax assets and liabilities for the tax effects of differences between the financial statements and tax basis of assets and liabilities. A valuation allowance is established to reduce the deferred tax assets if it is more likely than not that a deferred tax asset will not be realized. The components of income tax provision (benefit) related to continuing operations are as follows at December 31, 2019 and 2018: 2019 2018 Current - - Deferred - - Total tax provision - - The following is a reconciliation of the effective income tax rate with the statutory income tax rate at December 31, 2019 and 2018: 2019 2018 U.S. Federal statutory income tax rate (21.0 )% (21.0 )% State income tax, net of federal benefit (3.5 )% (1.9 )% Temporary differences, net 0.0 % 0.0 % Valuation allowance 24.5 % 22.9 % Effective tax rate 0.0 % 0.0 % The net deferred tax assets and liabilities included in the financial statements consist of the following amounts at December 31, 2019 and 2018: Deferred tax assets 2019 2018 Net operating loss carry forwards $ 9,324,000 $ 8,985,000 Accrued wages $ 74,000 Other: Less: valuation allowance (9,398,000 ) (8,985,000 ) Total - - Deferred tax liabilities Stock based compensation - - Depreciation - - Net deferred tax asset $ - $ - The change in valuation allowance was $413,000 and $407,612 for the years ended December 31, 2019 and 2018, respectively. We recorded a 100% valuation allowance related to the deferred tax asset for the loss from operations. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period in which temporary differences become deductible. The Company has net operating loss carryforwards of approximately $38.0 million as of December 31, 2019, of which $32.6 million were incurred prior to 2018 that begin to expire in the year 2032 through 2036. In accordance with the provisions of ASC 740: Income Taxes, we record a liability for uncertain tax positions when it is probable that a loss has been incurred and the amount can be reasonably estimated. At December 31, 2019 and 2018, we have no liabilities for uncertain tax positions. We continually evaluate expiring statutes of limitations, audits, proposed settlements, changes in tax law and new authoritative rulings.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 13 - COMMITMENTS AND CONTINGENCIES The Company is subject to asserted claims and liabilities that arise in the ordinary course of business. The Company maintains insurance policies to mitigate potential losses from these actions. In the opinion of management, the amount of the ultimate liability with respect to those actions will not materially affect the Company’s financial position or results of operations. As of December 31, 2019, the Company is not aware of any asserted claims.

Concentrations of Credit Risk

Concentrations of Credit Risk	12 Months Ended
	Dec. 31, 2019
Risks and Uncertainties [Abstract]
Concentrations of Credit Risk	NOTE 14 - CONCENTRATIONS OF CREDIT RISK a) Cash The Company maintains its cash in bank deposit accounts, which may, at times, may exceed federally insured limits. The Company had no cash balances in excess of FDIC insured limits at December 31, 2019 and $244,501 at 2018. b) Revenue Our principal customers are comprised of four (4) separate independent private label resellers that represent approximately 73% of the Company’s revenue. One of these customers represent 89% of accounts receivable. Should we lose one or more of these resellers our revenue would decline significantly.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2019
Subsequent Events [Abstract]
Subsequent Events	NOTE 15 - SUBSEQUENT EVENTS In December 2019, a novel strain of coronavirus (COVID-19) was reported to have surfaced in China, and began to spread around the world in early 2020. In reaction to decreased supply of and increased demand for sanitizer products, the Company shifted its manufacturing to produce sanitizer products. The Company’s other business operations have been impacted negatively by COVID-19 due to government restrictions and the overall adverse effect on the global economy. The Company expects COVID-19 to continue to negatively impact its operating results and its ability to obtain financing. During 2020, the Company issued warrants totaling 5,540,740 in exchange for cash proceeds of $125,000. The exercise prices range from $0.08 - $0.10 and expire 2 - 3 years after issuance. In January 2021, the Company issued 15,000,000 warrants to its Chief Executive Officer, President, and sole Director as compensation. The warrants have an exercise price of $0.1025 and expire 3 years after issuance. During January and February 2021, the Company issued warrants in connection with common stock issuances totaling 5,600,000. The warrants have an exercise price of $0.08 and expire 3 years after issuance. Litigation: In 2020, a claim has been filed against the Company by its former attorney. The claim involves allegations that fees approximating $150,000 charged for the calendar year 2019 were unpaid. The Company is vigorously contesting these claims and the outcome cannot be determined at this time. In 2020, a claim was filed against the Company for a breach of confidentiality imposed by a non-disclosure agreement signed by both the Company and plaintiff. The claim was dismissed in February 2021.

Basis of Presentation and Sum_2

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Basis of Presentation	a) Basis of Presentation The accompanying financial statements have been prepared in accordance with Generally Accepted Accounting Principles (“GAAP”) in the United States of America (“U.S.”) as promulgated by the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) and with the rules and regulations of the U.S Securities and Exchange Commission (“SEC”).
Reclassifications	b) Reclassifications Reclassifications occurred to certain prior year amounts in order to conform to the current year presentation. The reclassifications have no effect on the reported net loss.
Principles of Consolidation	c) Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Precision Analytic Testing, LLC, NutraDerma Technologies, Inc., PhytoChem Technologies, Inc. and TransDermalRX, Inc. We operate as one reportable segment. All material intercompany transactions and balances have been eliminated in consolidation.
Use of Estimates	d) Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.
Inventories	e) Inventories Inventories are stated at the lower of cost or net realizable value utilizing the weighted average method of valuation and consist of raw materials and finished goods. As of December 31, inventory consists of the following:
Allowance for Doubtful Accounts	f) Allowance for Doubtful Accounts We establish the existence of bad debts through a review of several factors including historical collection experience, current aging status of the customer accounts, and financial condition of our customers. The allowance for doubtful accounts is $1,500 and $31,000 as of December 31, 2019 and 2018, respectively. The activity for the allowance for doubtful accounts for the years ended December 31, 2019 and 2018 is as follows: Balance at Beginning of Year Charged to expense Deductions from Reserve Balance at End of Year Year ended December 31, 2019 $ 31,000 - 29,500 $ 1,500 Year ended December 31, 2018 $ - 31,000 - $ 31,000
Property and Equipment	g) Property and Equipment All property and equipment are recorded at cost and depreciated over their estimated useful lives, generally three, seven and twelve years, using the straight-line method. Leasehold improvements are depreciated over the shorter of their estimated useful lives, which is generally three years, or the related lease term. Upon sale or retirement, the cost and related accumulated depreciation are eliminated from their respective accounts, and the resulting gain or loss is included in the results of operations. Repairs and maintenance charges, which do not increase the useful lives of the assets, are charged to operations as incurred.
Revenue Recognition	h) Revenue Recognition The Company adopted ASU 2014-09, “Revenue from Contracts with Customers” (Topic 606) and other associated standards on January 1, 2018, using the modified retrospective method, which did not have a material impact on the timing and amount of product revenues. The new revenue recognition standard prescribes a five-step model that focuses on transfer of control and entitlement to payment when determining the amount of revenue to be recognized. Under the new guidance, an entity is required to perform the following five steps: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation. The Company generates revenues from the sale of products. The product is invoiced, and the revenue is recognized upon shipment or once transfer of risk has passed to the customer, which is the point at which the Company has satisfied its performance obligation. Payments received in advance from customers are recorded as customer deposits until earned, at which time revenue is recognized. We recognize certain revenues under bill and hold arrangements with two customers when the Company has fulfilled all of its performance obligations, the units are segregated for the specific customer only, and the goods are ready for physical transfer to the customer in accordance with their defined contract delivery schedule. For any requested bill and hold arrangement, we make an evaluation as to whether the bill and hold arrangement qualifies for revenue recognition. The customer must initiate the request for the bill and hold arrangement. The customer must make a fixed commitment to purchase the items. The risk of ownership is passed to the customer, and payment terms are not modified. The Company’s revenues accounted for under ASC 606 do not require significant estimates or judgments based on the nature of the Company’s revenue. The Company’s contracts do not include multiple performance obligations or variable consideration. All of the Company’s sales resulted from contracts with customers for the years ended December 31, 2019 and 2018.
Shipping and Handling Costs	i) Shipping and Handling Costs Shipping and handling costs are expensed as incurred and included in cost of sales. Billings for shipping and handling are reflected within sales in the accompanying consolidated statements of operations.
Income Taxes	j) Income Taxes The Company follows the provisions of ASC 740-10, Accounting for Uncertain Income Tax Positions. When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of ASC 740-10, the benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above should be reflected as a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination. The tax years 2017-2019 for the Company remain open for IRS audit. The Company has received no notice of audit or any notifications from the IRS for any of the open tax years.
Net Loss Per Share	k) Net Loss Per Share Basic loss per share excludes dilution and is computed by dividing the loss attributable to stockholders by the weighted-average number of shares outstanding for the period. Diluted loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that shared in the earnings of the Company. Diluted loss per share is computed by dividing the loss available to stockholders by the weighted average number of shares outstanding for the year and dilutive potential shares outstanding unless consideration of such dilutive potential shares would result in anti-dilution. For the years ended December 31, 2019 and 2018, respectively, the following warrants and convertible notes were excluded from the computation of net loss per share: 2019 2018 Warrants 21,819,858 18,210,402 Convertible Notes payable and accrued interest 3,900,727 1,325,000 25,720,585 19,535,402
Financial Instruments and Fair Value Measurements	l) Financial Instruments and Fair Value Measurements The carrying value of the Company’s current consolidated financial instruments, which include cash, accounts receivable accounts payable and accrued liabilities approximate their fair values because of the short-term maturities of these instruments. The carrying value of the Company’s indebtedness approximates their fair values because of the short-term maturities and rates of interest of these instruments.
Impairment of Long-Lived Assets	m) Impairment of Long-Lived Assets A long-lived asset is tested for impairment whenever events or changes in circumstances indicate that its carrying value amount may not be recoverable. An impairment loss is recognized when the carrying amount of the asset exceeds the sum of the undiscounted cash flows resulting from its use and eventual disposition. The impairment loss is measured as the amount by which the carrying amount of the long-lived assets exceeds its fair value. There were no impairments recognized during the years ended December 31, 2019 and 2018.
Advertising	n) Advertising Advertising costs are charged to operations as incurred and are included in operating expenses. The Advertising expenses are approximately $272,600 and $265,500 for the years ended December 31, 2019 and 2018, respectively.
Intangible Asset	o) Intangible Asset Intangible asset represents the value assigned to intellectual property and is amortized based on the economic benefit expected to be realized.
Leases	p) Leases On January 1, 2019, the Company adopted FASB ASU 2016-02, Leases (ASC 842) and other associated standards, which defines a lease as any contract that conveys the right to use a specific asset for a period of time in exchange for consideration. ASC 842 requires the recognition of the right-of-use assets and related operating and finance lease liabilities on the balance sheet and the disclosure of key information about certain leasing arrangements. As permitted by ASC 842, the Company elected the adoption date of January 1, 2019, which is the initial date of application. As a result, the consolidated balance sheet prior to January 1, 2019 was not restated, continues to be reported under ASC Topic 840, Leases, or ASC 840, which did not require the recognition of operating lease liabilities on the balance sheet, and is not comparative. Under ASC 842, all leases are required to be recorded on the balance sheet and are classified as either operating leases or finance leases (formerly called capital leases). The lease classification affects the expense recognition in the income statement. Operating lease charges are recorded entirely in operating expenses. Finance lease charges are split, where amortization of the right-of-use asset is recorded in operating expenses and an implied interest component is recorded in interest expense. The expense recognition for operating leases and finance leases under ASC 842 is substantially consistent with ASC 840. As a result, there is no significant difference in the Company’s results of operations presented in the consolidated statement of operations for each period presented. Leases are classified as a finance lease if any of the following criteria are met: 1. The lease transfers ownership of the underlying asset to the lessee by the end of the lease term. 2. The lease grants the lessee an option to purchase the underlying asset that the lessee is reasonably certain to exercise. 3. The lease term is for the major part of the remaining economic life of the underlying asset. 4. The present value of the sum of lease payments and any residual value guaranteed by the lessee equals or exceeds substantially all of the fair value of the underlying asset. 5. The underlying asset is of such a specialized nature that it is expected to have no alternative use to the lessor at the end of the lease term. For any leases that do not meet the criteria identified above for finance leases, the Company treats such leases as operating leases. As of December 31, 2019, the Company has two finance leases and three operating leases. Under the new guidance, both finance and operating leases are reflected on the balance sheet as lease or “right-of -use” assets and lease liabilities. There are some exceptions, which the Company has elected in its accounting policies. For leases with terms of twelve months or less, or below the Company’s general capitalization policy threshold, the Company elects an accounting policy to not recognize lease assets and lease liabilities for all asset classes. The Company recognizes lease expense for such leases generally on a straight-line basis over the lease term. The Company determines if a contract is a lease at the inception of the arrangement. The Company reviews all options to extend, terminate, or purchase its right-of-use assets at the inception of the lease and accounts for these options when they are reasonably certain to be exercised. Certain leases contain non-lease components, such as common area maintenance, which are generally accounted for separately. In general, the Company will assess if non-lease components are fixed and determinable, or variable, when determining if the component should be included in the lease liability. For purposes of calculating the present value of the lease obligations, the Company utilizes the implicit interest rate within the lease agreement when known and/or determinable, and otherwise utilizes its incremental borrowing rate at the time of the lease agreement. The related right-of-use asset is initially measured at cost, which primarily comprises of the initial amount of the lease liability. Lease expense for operating leases consists of the lease payments plus any initial direct costs and is recognized on a straight-line basis over the lease term. Included in lease expense are any variable lease payments incurred in the period that were not included in the initial lease liability. Lease expense for finance leases consists of the amortization of the right-of-use asset on a straight-line basis over the lease term and interest expense determined on an amortized cost basis. The lease payments are allocated between a reduction of the lease liability and interest expense. As permitted under ASU 2018-11, the Company elected the modified retrospective approach to adopt the new lease standard. Under this approach, the Company initially applied the new leases standard at the adoption date of January 1, 2019 and would have recognized a cumulative-effect adjustment, if appropriate, to the opening balance of retained earnings in the period of adoption. No cumulative-effect adjustment was recognized. The Company’s reporting for the comparative periods prior to 2019 in the financial statements will be presented in accordance with the existing U.S. GAAP in effect for 2018 and earlier (ASC Topic 840, Leases The impact of the adoption of ASC 842 on the balance sheet as of December 31, 2018 was: As Reported December 31, 2018 Adoption of ASC 842 Increase (Decrease) Balance, January 1, 2019 Operating Lease Right-of-Use-Asset $ - $ 781,030 $ 781,030 Total Assets $ 1,830,329 $ 781,030 $ 2,611,359 Operating Lease Liabilities-Current Portion $ - $ 88,121 $ 88,121 Total Current Liabilities $ 1,000,461 $ 88,121 $ 1,088,582 Operating Lease Liabilities-Net of Current Portion $ - $ 707,524 $ 707,524 Deferred Rent $ 14,614 $ (14,614 ) $ - Total Liabilities $ 1,015,075 $ 781,030 $ 1,796,105 Total Liabilities and Stockholders’ Equity $ 1,830,329 $ 781,030 $ 2,611,359
Recent Accounting Pronouncements	q) Recent Accounting Pronouncements In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15th, 2020, with early adoption permitted. The Company is currently evaluating the impact of this standard on its consolidated financial statements and related disclosures. In August 2020, the FASB issued ASU 2020-06, “Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity,” which simplifies and clarifies certain calculation and presentation matters related to convertible and equity and debt instruments. Specifically, ASU-2020-06 removes requirements to separately account for conversion features as a derivative under ASC Topic 815 and removing the requirement to account for beneficial conversion features on such instruments. Accounting Standards Update 2020-06 also provides clearer guidance surrounding disclosure of such instruments and provides specific guidance for how such instruments are to be incorporated in the calculation of Diluted EPS. The guidance under ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. The Company will adopt this standard using a modified retrospective approach effective January 1, 2021. The Company is currently evaluation the effects of adoption on its consolidated financial statements. Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying consolidated financial statements.

Basis of Presentation and Sum_3

Basis of Presentation and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Schedule of Inventories	2019 2018 Raw Materials $ 206,238 $ 219,638 Finished Goods 283,935 71,402 $ 490,173 $ 291,040
Schedule of Allowance for Doubtful Accounts	The activity for the allowance for doubtful accounts for the years ended December 31, 2019 and 2018 is as follows: Balance at Beginning of Year Charged to expense Deductions from Reserve Balance at End of Year Year ended December 31, 2019 $ 31,000 - 29,500 $ 1,500 Year ended December 31, 2018 $ - 31,000 - $ 31,000
Schedule of Warrants and Convertible Notes Excluded from Computation of Net Loss Per Share	For the years ended December 31, 2019 and 2018, respectively, the following warrants and convertible notes were excluded from the computation of net loss per share: 2019 2018 Warrants 21,819,858 18,210,402 Convertible Notes payable and accrued interest 3,900,727 1,325,000 25,720,585 19,535,402
Schedule of Impact of Adoption of ASC 842	The impact of the adoption of ASC 842 on the balance sheet as of December 31, 2018 was: As Reported December 31, 2018 Adoption of ASC 842 Increase (Decrease) Balance, January 1, 2019 Operating Lease Right-of-Use-Asset $ - $ 781,030 $ 781,030 Total Assets $ 1,830,329 $ 781,030 $ 2,611,359 Operating Lease Liabilities-Current Portion $ - $ 88,121 $ 88,121 Total Current Liabilities $ 1,000,461 $ 88,121 $ 1,088,582 Operating Lease Liabilities-Net of Current Portion $ - $ 707,524 $ 707,524 Deferred Rent $ 14,614 $ (14,614 ) $ - Total Liabilities $ 1,015,075 $ 781,030 $ 1,796,105 Total Liabilities and Stockholders’ Equity $ 1,830,329 $ 781,030 $ 2,611,359

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Summary of Property and Equipment	A summary of property and equipment at December 31, is as follows: 2019 2018 Furniture and equipment $ 1,959,694 $ 910,224 Leasehold improvements 840,728 374,934 Property and equipment, at cost 2,800,422 1,285,158 Less: accumulated depreciation (423,775 ) (359,350 ) $ 2,376,647 $ 925,808

Intangible Asset (Tables)

Intangible Asset (Tables)	12 Months Ended
	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Estimate Amortization Expense	The estimated annual amortization expense for the next five years and thereafter is as follows: 2020 $ 65,000 2021 65,000 2022 65,000 2023 65,000 2024 65,000 Thereafter 330,086 $ 655,086

Accrued Expenses (Tables)

Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2019
Payables and Accruals [Abstract]
Summary of Accrued Expenses	A summary of accrued expenses at December 31, is as follows: Name 2019 2018 Officer – Bonus $ 300,000 $ 200,000 Deferred rent - 15,393 Interest payable 42,059 - Miscellaneous Accrual 9,561 24,771 Royalty Fees - 85,000 Other current liabilities 61,574 - Accrued rent - 143,674 $ 413,194 $ 468,838

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2019
Leases [Abstract]
Schedule of Operating Leases Undiscounted Future Minimum Lease Payments	Undiscounted future minimum lease payments: 2020 $ 215,000 2021 221,000 2022 182,000 2023 184,000 2024 190,000 Thereafter 16,000 Total undiscounted future minimum lease payments 1,008,000 Less: amount representing imputed interest (213,000 ) Operating lease liability $ 795,000
Schedule of Finance Leases Undiscounted Future Minimum Lease Payments	Undiscounted future minimum lease payments: 2020 $ 24,000 2021 24,000 2022 17,000 2023 2,100 Total undiscounted future minimum lease payments 67,100 Less: amount representing interest (10,300 ) Less: current portion (20,000 ) Present value of minimum lease payments, net of current portion $ 36,800

Equity Warrants (Tables)

Equity Warrants (Tables)	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Schedule of Warrants Outstanding	At December 31, our warrants outstanding are as follows: By Exercise Price: 2019 2018 Warrants - $0.10 2,500,000 - Warrants - $0.20 13,302,941 2,950,000 Warrants - $0.30 722,800 - Warrants - $0.35 5,294,117 7,144,117 Warrants - $0.50 - 7,877,000 Warrants - $0.75 - 114,286 Warrants - $1.00 - 124,999 Total outstanding 21,819,858 18,210,402
Schedule of Warrants Activity	Warrants Balance, January 1, 2018 16,431,285 Warrants Issued 8,244,117 Warrants Exercised - Warrants Expired (6,465,000 ) Balance, December 31, 2018 18,210,402 Warrants Issued 13,575,741 Warrants Exercised - Warrants Expired (9,966,285 ) Balance, December 31, 2019 21,819,858

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Schedule of Income Tax Provision (Benefit)	The components of income tax provision (benefit) related to continuing operations are as follows at December 31, 2019 and 2018: 2019 2018 Current - - Deferred - - Total tax provision - -
Summary of Reconciliation of Statutory Federal Income Tax Rate	The following is a reconciliation of the effective income tax rate with the statutory income tax rate at December 31, 2019 and 2018: 2019 2018 U.S. Federal statutory income tax rate (21.0 )% (21.0 )% State income tax, net of federal benefit (3.5 )% (1.9 )% Temporary differences, net 0.0 % 0.0 % Valuation allowance 24.5 % 22.9 % Effective tax rate 0.0 % 0.0 %
Schedule of Deferred Tax Assets and Liabilities	The net deferred tax assets and liabilities included in the financial statements consist of the following amounts at December 31, 2019 and 2018: Deferred tax assets 2019 2018 Net operating loss carry forwards $ 9,324,000 $ 8,985,000 Accrued wages $ 74,000 Other: Less: valuation allowance (9,398,000 ) (8,985,000 ) Total - - Deferred tax liabilities Stock based compensation - - Depreciation - - Net deferred tax asset $ - $ -

Basis of Presentation and Sum_4

Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Allowance for doubtful accounts	$ 1,500	$ 31,000
Antidilutive securities	25,720,585	19,535,402
Asset impairment charges
Advertising expense	$ 272,600	$ 265,500
Options and Warrants [Member]
Antidilutive securities	21,819,858	18,210,402

Basis of Presentation and Sum_5

Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Inventories (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Accounting Policies [Abstract]
Raw Materials	$ 206,238	$ 219,638
Finished Goods	283,935	71,402
Inventories	$ 490,173	$ 291,040

Basis of Presentation and Sum_6

Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Allowance for Doubtful Accounts (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Accounting Policies [Abstract]
Balance at Beginning of Year	$ 31,000
Charged to expense		31,000
Deductions from Reserve	29,500
Balance at End of Year	$ 1,500	$ 31,000

Basis of Presentation and Sum_7

Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Warrants and Convertible Notes Excluded from Computation of Net Loss Per Share (Details) - shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Antidilutive Securities	25,720,585	19,535,402
Warrant [Member]
Antidilutive Securities	21,819,858	18,210,402
Convertible Notes Payable and Accrued Interest [Member]
Antidilutive Securities	3,900,727	1,325,000

Basis of Presentation and Sum_8

Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Impact of Adoption of ASC 842 (Details) - USD ($)	Dec. 31, 2019	Jan. 02, 2019	Dec. 31, 2018
Operating Lease Right-of-Use-Asset	$ 794,531	$ 781,030
Total Assets	4,465,691	2,611,359	1,830,329
Operating Lease Liabilities-Current Portion	141,674	88,121
Total Current Liabilities	2,186,744	1,088,582	1,000,462
Operating Lease Liabilities-Net of Current Portion	653,057	707,524
Deferred Rent
Total Liabilities	2,876,574	1,796,105	1,015,076
Total Liabilities and Stockholders, Equity	$ 4,465,691	$ 2,611,359	1,830,329
Adoption of ASC 842 Increase (Decrease) [Member]
Operating Lease Right-of-Use-Asset			781,030
Total Assets			781,030
Operating Lease Liabilities-Current Portion			88,121
Total Current Liabilities			88,121
Operating Lease Liabilities-Net of Current Portion			707,524
Deferred Rent			(14,614)
Total Liabilities			781,030
Total Liabilities and Stockholders, Equity			781,030
As Reported [Member]
Operating Lease Right-of-Use-Asset
Total Assets			1,830,329
Operating Lease Liabilities-Current Portion
Total Current Liabilities			1,000,461
Operating Lease Liabilities-Net of Current Portion
Deferred Rent			14,614
Total Liabilities			1,015,075
Total Liabilities and Stockholders, Equity			$ 1,830,329

Liquidity and Going Concern C_2

Liquidity and Going Concern Considerations (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss	$ (4,007,403)	$ (2,074,537)
Accumulated deficit	$ (38,840,861)	$ (34,833,458)

Property and Equipment, Net (De

Property and Equipment, Net (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 64,849	$ 66,033

Property and Equipment, Net - S

Property and Equipment, Net - Summary of Property and Equipment (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Property and equipment, at cost	$ 2,800,422	$ 1,285,158
Less: accumulated depreciation	(423,775)	(359,350)
Property and equipment, net	2,376,647	925,808
Furniture and Equipment [Member]
Property and equipment, at cost	1,959,694	910,224
Leasehold Improvements [Member]
Property and equipment, at cost	$ 840,728	$ 374,934

Intangible Asset (Details Narra

Intangible Asset (Details Narrative) - USD ($)	1 Months Ended			12 Months Ended
	Feb. 28, 2019	Dec. 31, 2018	Feb. 28, 2018	Dec. 31, 2019	Dec. 31, 2018
Paymets to acquire intangible assets				$ 130,000
Stock issued during period, shares, purchase of assets		1,696,968	2,000,000
Stock issued during period, value, purchase of assets		$ 105,229	$ 569,200		105,229
Amortization				$ 59,554
Common Stock [Member]
Stock issued during period, shares, purchase of assets					1,696,668
Stock issued during period, value, purchase of assets					$ 170
Patents [Member]
Consideration to acquire intangible assets	$ 714,640
Paymets to acquire intangible assets	$ 130,000
Remaining estimated useful life	11 years
Patents [Member] | Common Stock [Member]
Stock issued during period, shares, purchase of assets	3,300,000
Shares issued, price per share	$ 0.177
Stock issued during period, value, purchase of assets	$ 584,640
Issuance of shares description	Of the 3,300,000 shares, 1,800,000 shares were provided at closing and 1,500,000 were to be provided one year thereafter.

Intangible Asset - Schedule of

Intangible Asset - Schedule of Estimate Amortization Expense (Details)	Dec. 31, 2019USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2020	$ 65,000
2021	65,000
2022	65,000
2023	65,000
2024	65,000
Thereafter	330,086
Estimated Annual Amortization Expense	$ 655,086

Accrued Expenses - Summary of A

Accrued Expenses - Summary of Accrued Expenses (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Payables and Accruals [Abstract]
Officer - Bonus	$ 300,000	$ 200,000
Deferred rent		15,393
Interest payable	42,059
Miscellaneous Accrual	9,561	24,771
Royalty Fees		85,000
Other current liabilities	61,574
Accrued rent		143,674
Accrued Liabilities	$ 413,194	$ 468,838

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended	12 Months Ended
	Nov. 30, 2018	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Mar. 31, 2019	Oct. 31, 2018
Proceeds from issuance of stock				$ 106,280
Amortization of debt issuance costs and discounts				72,166
Proceeds from issuance of warrants			$ 125,000
Debt instrument, beneficial conversion feature				127,900
Amortization of debt discount				585,519	$ 105,763
Two Short Term [Member]
Debt instrument interest rate							10.00%
Number of warrants issued							2,000,000
Debt instrument face amount							$ 75,000
Short Term Promissory Note [Member]
Debt instrument, maturity date, description	Due in December of 2018
Debt instrument interest rate	10.00%
Debt conversion price per share	$ 0.20
Debt instrument face amount	$ 25,000
Share based payment award number of shares available for grant	50,000					100,000
Noteholders [Member]
Shares were issued		418,800
Warrant [Member]
Proceeds from issuance of warrants				247,800
Debt instrument, beneficial conversion feature				134,054
Amortization of debt discount				$ 97,785
Expected term of contractual life				12 months
Expected annual volatility				154.80%
Expected dividend rate				0.00%
Expected risk-free interest rate				2.50%
Warrant [Member] | Noteholders [Member]
Number of warrants issued		3,222,800		3,222,800
Warrant One [Member]
Number of warrants issued		722,800		722,800
Warrants exercise price		$ 0.30		$ 0.30
Warrants, term		1 year		1 year
Warrant Two [Member]
Number of warrants issued		2,500,000		2,500,000
Warrants exercise price		$ 0.10		$ 0.10
Minimum [Member]
Warrants exercise price			$ 0.08
Maximum [Member]
Warrants exercise price			$ 0.10
Convertible Notes Payable [Member]
Proceeds from notes payable		$ 455,000
Debt instrument, maturity date, description		Due in November and December of 2020
Convertible Notes Payable [Member] | Minimum [Member]
Debt instrument interest rate		10.00%		10.00%
Debt conversion price per share		$ 0.085		$ 0.085
Convertible Notes Payable [Member] | Maximum [Member]
Debt instrument interest rate		12.00%		12.00%
Debt conversion price per share		$ 0.10		$ 0.10

Convertible Notes Payable to _2

Convertible Notes Payable to Shareholder (Details Narrative) - USD ($)	Apr. 02, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2019	Dec. 31, 2018
Value of stock issued during the period				$ 2,781,659	$ 618,332
Amortization of debt discount				585,519	$ 105,763
Short Term Promissory Note Payable [Member]
Proceeds form note payable			$ 200,000
Annual interest rate			3.00%
Maturity date			Apr. 20, 2019
Debt conversion shares issued	2,352,941
Debt conversion price per share	$ 0.085
Secured Convertible 5.75% Promissory Note Payable [Member]
Amortization of debt discount				$ 31,836
Secured Convertible 5.75% Promissory Note Payable [Member] | Investment Agreement [Member]
Proceeds form note payable		$ 1,000,000
Annual interest rate		5.75%
Maturity date		Dec. 7, 2020
Debt instrument, payment terms		The payment terms of the note are interest only payments from July 7, 2019 through December 7, 2019 and commencing January 7, 2020, the Company was to make equal monthly installment payments that include principal and interest through the Maturity Date of December 7, 2020.
Stock issued during the period, shares		500,000
Royalty percentage on revenue		8.50%
Royalty payment period		10 years
Value of stock issued during the period		$ 95,500
Secured Convertible 5.75% Promissory Note Payable [Member] | Investment Agreement [Member] | Thereafter Two Collateral Processors [Member]
Royalty percentage on revenue		5.00%

Stockholders' Equity (Details N

Stockholders' Equity (Details Narrative) - USD ($)	Nov. 02, 2018	Nov. 30, 2020	Mar. 31, 2019	Dec. 31, 2018	Feb. 28, 2018	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2012	Feb. 28, 2021	Sep. 30, 2020
Preferred stock, shares authorized				10,000			10,000	10,000
Value of stock issued during the period							$ 2,781,659	$ 618,332
Shares issued to settle accounts payable					169,159		934,000
Value of shares issued to settle accounts payable					$ 49,494		$ 93,400
Value of shares issued for services							610,987	1,070,050
Beneficial Conversion features, warrants issued in connection with convertible debt							127,900	18,888
Accounts payable				$ 243,502	31,490		$ 172,987	243,502
Loss on settlement of accounts payable					$ 18,004
Stock issued for acquisition of equiment				1,696,968	2,000,000
Value of stock issued for acquisition of equiment				$ 105,229	$ 569,200			$ 105,229
Number of shares returned	2,000,000
Preferred stock par value				$ 0.001			$ 0.001	$ 0.001
Subsequent Event [Member]
Stock issued during the period, shares						1,932,076
Warrants exercise price										$ .08
Per share price of stock						$ 0.065
Shares issued in connection with convertible debt						3,150,000
Common Stock [Member]
Shares issued for services							3,190,432	4,976,849
Warrant [Member]
Beneficial Conversion features, warrants issued in connection with convertible debt							$ 375,700
Investment Agreement [Member] | Third Party Lender [Member]
Investment			$ 2,000,000
Proceeds for investment								$ 380,000
Number of restricted stock issued, value			$ 1,000,000
Number of restricted stock issued			13,764,705
Warrants to purchase common stock			10,000,000
Warrants exercise price			$ 0.20
Warrants value			$ 2,000,000
Warrants expiry date			Mar. 4, 2022
Options to purchase shares			7,647,058
Options purchase price			$ 0.085
Fair value of options			$ 650,000
Series A Preferred Stock [Member]
Preferred stock, shares authorized							1,000
Preferred stock, voting rights							Each share has voting rights equal to 500,000 shares of the Company's common stock.
Stock issued during the period, shares									1,000
Value of stock issued during the period									$ 1,000
Series B Convertible Preferred Stock [Member]
Preferred stock, shares authorized											110
Preferred stock par value											$ 0.0001
Terms of conversion							The shares of Series B Preferred Stock are convertible at a rate of 1 share of Series B Preferred Stock to 149,567 shares of common stock, par value $0.0001 per share of the Company (the “Common Stock”). Holders of Series B Preferred Stock of the Company may convert their shares of Series B Preferred Stock into Common Stock at any time following January 1, 2021 (the “Permitted Conversion Date”).
Series X Preferred Stock [Member] | Stock Purchase Agreement [Member] | Subsequent Event [Member] | Lord Global Corporation [Member]
Stock issued during the period, shares		12,500,000
Shares issued in connection with convertible debt		250
Series B Preferred Stock [Member] | Subsequent Event [Member]
Preferred stock, shares authorized						110
Preferred stock par value						$ 0.0001
Convertible preferred stock shares issued						20

Leases (Details Narrative)

Leases (Details Narrative) - USD ($)	1 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2019	Dec. 31, 2018	Jan. 02, 2019
Operating lease, right-of-use asset		$ 794,531		$ 781,030
Operating lease liability		795,000
Operating lease, current liability		$ 141,674		$ 88,121
Weighted average remaining lease term		54 months
Weighted average discount rate		10.00%
Operating lease expense		$ 297,000	256,000
Finance lease equipment		$ 110,372	$ 19,179
Phytochem [Member]
Description of operating lease		In July and September of 2019, the Company's wholly owned subsidiary, Phytochem, entered into two separate lease agreements for office and warehouse space located in Onalaska, Wisconsin, that commenced on August 1 and October 1, respectively. Each lease is for six-month terms with four (4) renewal options to extend for six additional months. The Company expects to occupy these facilities for the full term of these leases totaling 30 months and the leases call for annual 3% increases to base rent.
Lessee, operating lease, term of contract		30 months
Annual increases to base rent percent		3.00%
Operating lease, option to extend		Each lease is for six-month terms with four (4) renewal options to extend for six additional months
Coconut Creek, Florida [Member]
Operating lease expires, date		2022-02
Deerfield Beach, Florida [Member]
Description of operating lease	the Company entered into a lease for an additional facility located in Deerfield Beach, Florida under a non-cancelable operating lease. The term of the lease is for 86 months beginning on January 1, 2018 and calls for yearly 3% increases to base rent, with monthly payments that commenced in March 2018.
Lessee, operating lease, term of contract		86 months
Annual increases to base rent percent		3.00%

Leases - Schedule of Operating

Leases - Schedule of Operating Leases Undiscounted Future Minimum Lease Payments (Details)	Dec. 31, 2019USD ($)
LEASES (Details)
2020	$ 215,000
2021	221,000
2022	182,000
2023	184,000
2024	190,000
Thereafter	16,000
Total undiscounted future minimum lease payments	1,008,000
Less: amount representing imputed interest	(213,000)
Operating lease liability	$ 795,000

Leases - Schedule of Finance Le

Leases - Schedule of Finance Leases Undiscounted Future Minimum Lease Payments (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
LEASES (Details 1)
2020	$ 24,000
2021	24,000
2022	17,000
2023	2,100
Total undiscounted future minimum lease payments	67,100
Less: amount representing interest	(10,300)
Less: current portion	20,000	$ 3,836
Present value of minimum lease payments, net of current portion	$ 36,773	$ 14,614

Equity Warrants - Schedule of W

Equity Warrants - Schedule of Warrants Outstanding (Details) - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Warrants outstanding	21,819,858	18,210,402
Warrant [Member]
Warrants outstanding	22,819,858	18,210,402	16,431,285
Warrants Issued	27,151,482	8,244,117
Warrants Exercised
Warrants Expired	(23,542,026)	(6,465,000)
Exercise price 1 [Member]
Warrants outstanding	2,500,000
Exercise price	$ 0.10	$ 0.10
Exercise price 2 [Member]
Warrants outstanding	13,302,941	2,950,000
Exercise price	$ 0.20	$ 0.20
Exercise price 3 [Member]
Warrants outstanding	722,800
Exercise price	$ 0.30	$ 0.30
Exercise price 4 [Member]
Warrants outstanding	5,294,117	7,144,117
Exercise price	$ 0.35	$ 0.35
Exercise price 5 [Member]
Warrants outstanding		7,877,000
Exercise price	$ 0.50	$ 0.50
Exercise price 6 [Member]
Warrants outstanding		114,286
Exercise price	$ 0.75	$ 0.75
Exercise price 7 [Member]
Warrants outstanding		124,999
Exercise price	$ 1	$ 1

Equity Warrants - Schedule of_2

Equity Warrants - Schedule of Warrants Activity (Details) - shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Warrants and Rights Note Disclosure [Abstract]
Warrants outstanding, beginning balance	18,210,402	16,431,285
Warrants Issued	13,575,741	8,244,117
Warrants Exercised
Warrants Expired	(9,966,285)	(6,465,000)
Warrants outstanding, ending balance	21,819,858	18,210,402

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Change in valuation allowance	$ 413,000	$ 407,612
Percentages of valuation allowance recorded	100.00%
Net operating loss carryforwards	$ 38,000,000

Income Taxes - Schedule of Inco

Income Taxes - Schedule of Income Tax Provision (Benefit) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Taxes - Schedule Of Income Tax Provision Benefit
Current
Deferred
Total tax provision

Income Taxes - Summary of Recon

Income Taxes - Summary of Reconciliation of Statutory Federal Income Tax Rate (Details)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
U.S. Federal statutory income tax rate	(21.00%)	(21.00%)
State income tax, net of federal benefit	(3.50%)	(1.90%)
Temporary differences, net	0.00%	0.00%
Valuation allowance	24.50%	22.90%
Effective tax rate	0.00%	0.00%

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Deferred tax assets: Net operating loss carry forwards	$ 9,324,000	$ 8,985,000
Deferred tax assets: Accrued wages	74,000
Less: valuation allowance	(9,398,000)	(8,985,000)
Total
Deferred tax liabilities: Stock based compensation
Deferred tax liabilities: Depreciation
Net deferred tax asset

Concentrations of Credit Risk (

Concentrations of Credit Risk (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Cash balances	$ 244,501
Revenue [Member] | Customer [Member] | Four Separate Independent Private [Member]
Concentration risk, percentage	73.00%
Accounts Receivable [Member] | Customer [Member]
Concentration risk, percentage	89.00%

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	1 Months Ended	2 Months Ended	12 Months Ended
	Jan. 31, 2021	Feb. 28, 2021	Dec. 31, 2020
Number of warrants issued			5,540,740
Cash proceeds from warrants			$ 125,000
Subsequent Event [Member]
Number of warrants issued		5,600,000
Warrants exercise price		$ .08
Warrants expiry term		3 years
Subsequent Event [Member] | Chief Executive Officer President andDirector [Member]
Number of warrants issued	15,000,000
Warrants exercise price	$ .1025
Warrants expiry term	3 years
Subsequent Event [Member] | Former Attorney [Member]
Damages sought value			$ 150,000
Minimum [Member]
Warrants exercise price			$ 0.08
Warrants expiry term			2 years
Maximum [Member]
Warrants exercise price			$ 0.10
Warrants expiry term			3 years